Intro

Cancer therapies vary in their effectiveness and in most instances, standard treatment regimens are unsuccessful in a majority of patients — it has been estimated that overall objective response rates to cancer therapies is only 25%.  And for some cancers, it may be even lower.

For example, in a retrospective study, the likelihood of response was discouragingly low:

A retrospective analysis of 43 patients with advanced NSCLC who had received 3rd- or 4th-line chemotherapy after two prior regimens that included platinum and docetaxel given concurrently or sequentially.
NCCN = National Comprehensive Cancer Network; NSCLC = non-small-cell lung cancer.

Use your patient’s own tumor to help individualize your treatment approach.

Champions Personalized TumorGrafts is a personalized, in vivo model that delivers tumor-specific data to help you select the optimal treatment regimen for your patient.

Tumors that have been tested successfully using TumorGraft testing include cancers of the colon, pancreas, stomach, esophagus, lung, and breast, as well as sarcomas and others.

Learn how the Personalized TumorGraft process works >

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology